Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM.

Clin Genitourin Cancer. 2019 Feb;17(1):1-6. doi: 10.1016/j.clgc.2018.09.005. Epub 2018 Sep 12.

PMID:
30287223
2.

Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation.

Cermakova K, Hodges HC.

Molecules. 2018 Aug 6;23(8). pii: E1958. doi: 10.3390/molecules23081958. Review.

3.

Switching of the folding-energy landscape governs the allosteric activation of protein kinase A.

England JP, Hao Y, Bai L, Glick V, Hodges HC, Taylor SS, Maillard RA.

Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7478-E7485. doi: 10.1073/pnas.1802510115. Epub 2018 Jul 23.

4.

Affinity switching of the LEDGF/p75 IBD interactome is governed by kinase-dependent phosphorylation.

Sharma S, Čermáková K, De Rijck J, Demeulemeester J, Fábry M, El Ashkar S, Van Belle S, Lepšík M, Tesina P, Duchoslav V, Novák P, Hubálek M, Srb P, Christ F, Řezáčová P, Hodges HC, Debyser Z, Veverka V.

Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):E7053-E7062. doi: 10.1073/pnas.1803909115. Epub 2018 Jul 11.

5.

Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers.

Hodges HC, Stanton BZ, Cermakova K, Chang CY, Miller EL, Kirkland JG, Ku WL, Veverka V, Zhao K, Crabtree GR.

Nat Struct Mol Biol. 2018 Jan;25(1):61-72. doi: 10.1038/s41594-017-0007-3. Epub 2017 Dec 11.

Supplemental Content

Loading ...
Support Center